Kalaris Therapeutics, Inc., headquartered in Palo Alto, California, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company was founded in 2019 and underwent a significant transformation in March 2025 through a merger with AlloVir, Inc., resulting in the combined entity retaining the Kalaris Therapeutics name and trading on the Nasdaq Global Market under the ticker symbol KLRS.
The company's primary focus is on TH103, a novel, differentiated anti-vascular endothelial growth factor (anti-VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein designed to act as a decoy receptor against VEGF, aiming to provide improved VEGF inhibition and longer retention in the retina. This therapeutic candidate is currently being evaluated in an ongoing Phase 1 clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to expand its application to other neovascular and exudative retinal diseases such as diabetic macular edema (DME) and retinal vein occlusion (RVO).
The merger with AlloVir has bolstered Kalaris's financial position, providing approximately $100 million in cash reserves. This funding is expected to support the company's operating expenses and capital expenditure requirements into the fourth quarter of 2026, facilitating the advancement of TH103 through clinical development.
Kalaris Therapeutics is led by CEO Andrew Oxtoby and supported by a management team with expertise in ophthalmology and biopharmaceutical development. The company's strategic focus on innovative retinal therapies underscores its commitment to addressing unmet medical needs in ophthalmology and improving patient outcomes in retinal diseases.